The UK medicines regulator identified 30 cases of rare blood clots after the use of AstraZeneca’s Covid-19 vaccine.
But the Medicines and Healthcare Products Regulatory Agency said the benefits of the vaccine still far outweighed the potential risk, with more than 18 million AstraZeneca doses administered in the UK.
No blood clotting reports were received for the vaccine developed by Pfizer and BioNTech.
Officials said 18.1 million doses of AstraZeneca’s vaccine had been administered up to March 24.
Of these, there were “22 reports of cerebral venous sinus thrombosis and eight reports of other thrombosis events with low platelets”.
Some countries are restricting use of the AstraZeneca vaccine while others resumed inoculations as investigations into reports of rare, and sometimes severe, blood clots continue.
Germany this week stopped general use of AstraZeneca’s shot in people aged under 60.